Are we negating the benefits of CABG by forgetting secondary prevention?

Journal of Human Hypertension

Volumn 16, Issue 10, 2002, Pages 691-697

  Belcher, P R ^a   Gaw, A ^a   Cooper, M ^a   Brown, M ^b   Wheatley, D J ^a   Lindsay, G M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Pollokshaws Medical Centre   (United Kingdom)

Author keywords

Angina; Coronary; Hypertension; Risk factor; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; NITRATE; VASOACTIVE AGENT; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ANKLE EDEMA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRESCRIPTION; RISK FACTOR; SECONDARY PREVENTION; SELF REPORT; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

ANGINA PECTORIS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CORONARY ARTERY BYPASS; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; STATISTICS, NONPARAMETRIC;

EID: 0036812544     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001469     Document Type: Article

References (32)

1. Lindsay GM, Smith LN, Hanlon P, Wheatley DJ. The influence of general health status and social support on symptomatic outcome following coronary artery bypass grafting. Heart 2001; 85: 80-86.
2. National Institute of Health Consensus. Development Conference Statement: coronary artery bypass surgery: scientific and clinical aspects. N Engl J Med 1981; 304: 680-684.
3. Sever P et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. Br Med J 1993; 306: 983-987.
4. Ramsay LE et al. British Hypertension Society guidelines for hypertension management 1999: summary. Br Med J 1999; 319: 630-635.
5. Herlitz J et al. Mortality, risk indicators, mode and place of death and symptoms of angina pectoris in the five years after coronary bypass grafting in patients with and without a history of hypertension. Blood Press 1999; 8: 200-206.
6. Sjoland H et al. Improvement in various estimates of quality of life after bypass grafting in patients with and without a history of hypertension. J Hypertens 1997; 15: 1033-1039.
7. Kee KA, Kieckhefer GM. Measuring human responses using visual analog scales. Western J Nurs Res 1989; 11: 128-132.
8. Campeau L. Grading of angina pectoris [Letter]. Circulation 1975; 52: 522.
9. Criteria Committee for the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Blood Vessels, 7th Edn. Little Brown and Company: Boston, 1974.
10. Castelli WP. Epidemiology of coronary heart disease: The Framingham study. Am J Med 1984; 76 (Suppl 2A): 4-12.
11. CABRI Trial. Participants first-year results of CABRI (Coronary Angioplasty vs Bypass Revascularisation Investigation). Lancet 1995; 346: 1179-1184.
12. Pocock SJ et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation 1996; 94: 135-142.
13. Shaper AG et al. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Commun Health 1985; 39: 197-209.
14. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997; 6: 357-364.
15. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
16. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
17. Zabalgoitia M et al. Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study). Am J Cardiol 2001; 88: 521-525.
18. Enbergs A et al. Secondary prevention of coronary heart disease: Ideal versus reality in the Munster EURASPIRE study population. Z Kardiol 1997; 86: 284-291.
19. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: Survey in primary care. Br Med J 2001; 322: 1463.
20. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thrombo-embolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-691.
21. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
22. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
23. Brown WV. Cholesterol lowering in atherosclerosis. Am J Cardiol 2000; 86 (4B): 29H-32H.
24. Koh KK et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coronary Artery Dis 2001; 12: 305-311.
25. Flaker GC et al. Pravastatin prevents clinical events in revascularised patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999; 34: 106-112.
26. Cook DG, Shaper AG. Breathlessness, angina pectoris and coronary artery disease. Am J Cardiol 1989; 63: 921-924.
27. Oparil S et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18: 608-625.
28. Skinner JS et al. Patient-related outcomes five years after coronary bypass graft surgery. Q J Med 1999; 92: 87-96.
29. Delacretaz E et al. Secondary prevention of ischemic heart disease after coronary revascularization. Schweiz Runsch Med Prax 1998; 87: 1497-1503.
30. Oldenburg B, Pierce J, Sicree R, Ross D. Coronary risk factor outcomes following coronary artery bypass surgery. Aust NZ J Med 1989; 19: 234-240.
31. McHugh F et al. Nurse-led shared care for patients on the waiting list for CABG: A randomised controlled trial. Heart 2001; 86: 317-323.
32. Campbell NC et al. Secondary prevention in coronary heart disease: A randomised trial of nurse led clinics in primary care. Heart 1998; 80: 447-452.